Reported 2 days ago
Johnson & Johnson (NYSE: JNJ), a leading player in the pharmaceutical and medical device sectors with a market value nearing $425 billion, has reinforced its reputation as a prime dividend-paying stock, boasting a 63-year history of dividend growth. The company's recent Q2 results indicated a 5.8% increase in revenue and an 18% rise in earnings. Although the consumer healthcare division was recently spun off into Kenvue, JNJ continues to expand its portfolio with significant offerings in immunology and oncology, alongside 40 late-stage clinical trials. With a quarterly dividend of $1.30 and a yield of 2.95%, it remains popular among income investors.
Source: YAHOO